Download file (2.23MB)
Download as zip (1.84MB)

コレクション

引用

説明:

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related morbidity
worldwide. Sorafenib is a first-line drug for the treatment of HCC, however, it is reported to
cause serious adverse effects and may lead to resistance in many patients. In this study, 20
hydrazone derivatives incorporating triazoles, pyrazolone, pyrrole, pyrrolidine, imidazoline,
quinazoline, and oxadiazine moieties were designed, synthesized, and characterized. In
addition to molecular docking and in silico ADME study, the cytotoxic activity of the
synthesized compounds was evaluated against the human hepatocellular cancer cell line
(HepG2) and liver mesenchymal stem cells as a normal cell line. The antitumor activities of
the derivatives against sorafenib were compared. Of the 20 synthesized compounds,
compound 16 demonstrated potential as a potent anti-HCC drug candidate through
downregulation of interleukin 6 which reduces inflammation and tumorigenesis with a strong
binding interaction and bioavailability.

権利情報:

• cc-by-3.0
  

キーワード: HCC, IL-6, hydrazone derivatives, antitumor, cytochrome c, molecular docking simulation, Sorafenib, 5-fluoruracil, hepatocellular carcinoma.

刊行年月日: 2024-11-28

出版者: Royal Society of Chemistry (RSC)

掲載誌:

• RSC Advances (ISSN: 20462069) vol. 14 issue. 51 p. 37960-37974

研究助成金:

• American University in Cairo

原稿種別: 出版者版 (Version of record)

MDR DOI:

公開URL: https://doi.org/10.1039/d4ra05854b

関連資料:

その他の識別子:

連絡先:

更新時刻: 2024-12-04 14:53:06 +0900

MDRでの公開時刻: 2024-12-04 14:53:06 +0900